Lung Cancer Therapeutics: Market Research Report
This report analyzes the worldwide markets (Annual Revenues) for Lung Cancer Therapeutics in Millions of US$.
The US market for Non-Small Cell Lung Cancer treatment is further analyzed by: Chemotherapy Drugs, and Targeted Drugs.
The report provides separate comprehensive analytics for the US, Europe and Rest of World.
Annual forecasts are provided for each region for the period 2005 through 2015.
The report profiles 191 companies including many key and niche players worldwide such as AstraZeneca PLC., Bristol-Myers Squibb Co., Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline Plc., Novartis Pharmaceuticals Corporation, OSI Pharmaceuticals, Inc., Sanofi-Aventis, AbGenomics International Inc., ImClone Systems, Inc., Pfizer, Inc., Merck Serono International S.A., Merck & Co.Ltd., Telik, Inc., and Woomera Therapeutics, Inc.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
The US market for Non-Small Cell Lung Cancer treatment is further analyzed by: Chemotherapy Drugs, and Targeted Drugs.
The report provides separate comprehensive analytics for the US, Europe and Rest of World.
Annual forecasts are provided for each region for the period 2005 through 2015.
The report profiles 191 companies including many key and niche players worldwide such as AstraZeneca PLC., Bristol-Myers Squibb Co., Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline Plc., Novartis Pharmaceuticals Corporation, OSI Pharmaceuticals, Inc., Sanofi-Aventis, AbGenomics International Inc., ImClone Systems, Inc., Pfizer, Inc., Merck Serono International S.A., Merck & Co.Ltd., Telik, Inc., and Woomera Therapeutics, Inc.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Chemotherapy Drugs
Targeted Drugs
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Lung Cancer Therapeutics – Driven by Next Generation Drugs
New Therapies Drive NSCLC Market
Market Value of Taxanes to Decrease by 2015
Lung Cancer – The Killer Disease
Lung Cancer – A Quick Glance at Global Statistics
Asia Heading for Possible Lung Cancer Epidemic
2. LUNG CANCER – AN INSIGHT
Lungs – Critical for Oxygen Supply
Lung Cancer – An Introduction
Common Symptoms of Lung Cancer
Types of Lung Cancer
Non-Small Cell Lung Cancer
NSCLC – At a Glance
Small Cell Lung Cancer
Risk Factors for Lung Cancer
Female Smokers at Higher Risk of Developing Lung Cancer
Lung Cancer Diagnostics
Lung Cancer Staging
Staging for Non-Small Cell Lung Cancer
Staging for Small Cell Lung Cancer
3. LUNG CANCER TREATMENT MODALITIES
Surgery
Radiation Therapy
Chemotherapy
Combination Therapy
Photodynamic Therapy
Vaccines
Common Treatment Modalities for SCLC and NSCLC Lung Cancers
Pain Management
4. INTRODUCTION TO LUNG CANCER THERAPEUTICS
Chemotherapy
Drug Administration
Overview of Chemotherapy Regimens and Drugs
Side Effects of Chemotherapy
Targeted Therapy
Chemotherapy Drugs for SCLC Treatment
Chemotherapy Drugs for NSCLC Treatment
Major Chemotherapy Drugs
Select Chemotherapy Drugs Used in the Treatment of Lung Cancer by Brand and Generic Name
Overview of Select Chemotherapeutic Drugs
Alimta
Carboplatin and Cisplatin
Docetaxel
Paclitaxel
Xyotax
Gemcitabine
Gefitinib
Irinotecan
Vinorelbine (Navelbine®)
5. PRODUCT DEVELOPMENT IN NSCLC THERAPEUTICS
R&D Focus in NSCLC Treatment
Drug Development Process – Growth Opportunities & Challenges
Product Pipeline for NSCLC Treatment
Product Pipeline for NSCLC Treatment
Select (Ongoing/Completed) Clinical Trials for NSCLC Treatment
Companies Focus on Molecular Targeted Therapies
Molecular Targeted Therapies – Overview of Select Product Candidates
Aflibercept (VEGF-Trap) – Sanofi Aventis/ Regeneron
BIBW 2992 – Boehringer Ingelheim
Erbitux (cetuximab) - ImClone/Merck Serono/Bristol- Myers Squibb
Nexavar (sorafenib) - Bayer Schering
Recentin (cediranib) – AstraZeneca
Sutent (sunitinib) – Pfizer
Zactima (vandetanib) – AstraZeneca
Zolinza (vorinostat) – Merck & Co
Pipeline for Cytotoxic Therapy – Overview of Select Products
Abraxane (albumin-bound paclitaxel) - Abraxis
Glutoxim (NOV-002) - Novelos
Javlor (vinflunine) – Pierre Fabre
Lipoplatin (liposomal cisplatin) – Regulon
Xyotax (paclitaxel polyglumex) - Cell Therapeutics/ Novartis
6. PRODUCT APPROVALS/INNOVATIONS/ LAUNCHES
Intas Biopharmaceuticals to Introduce Gefitinib in India
Celgene Receives FDA Fast Track Product Designation for Amrubicin
EMEA Approves ALIMTA for First-Line Therapy of Advanced NSCLC
Celgene’s Cancer Drug Receives Orphan Drug Status from European Commission
Alimta Receives FDA Approval
Roche Receives Approval from European Authorities for Avastin
OSI Pharmaceuticals Introduces Tarceva in Japan
Shanghai Medipharm Introduces TNT Antibody for Treating Lung Cancer
Natco Pharma Unveils an Injectible Drug for Lung Cancer, Pemnat
Roche Scientific Introduces Tarceva in the Indian Market
GlaxoSmithKline’s HYCAMTIN® Receives Marketing Approval from EC
Genzyme Launches New Genetic Mutation Test to Aid Lung Cancer Treatment
UT Southwestern Medical Center Researchers Discover New Anti-Cancer Drug
Agennix's Talactoferrin Alfa Program Obtains Fast Track Designation from FDA
Novelos Therapeutics’ NOV-002 Receives Fast Track Designation from FDA
7.RESEARCH & CLINICAL TRIALS
Novartis Commences Phase III Clinical Trial of ASA404
Results of BR.21 Trials
Genentech Announces Results of Phase III BETA Lung Trial
Results of SATURN Clinical Trial
Results of Zactima’s Clinical Trials
Results of Erbitux’s Phase III Trials
Results of Roche’s AVAiL Clinical Trial
GlaxoSmithKline Conducts Phase III Clinical Trial of Lung Cancer Vaccine
FASgen Announces Research Results of FAS093
The Cuban Regulatory Agency Registers a New Therapeutic Lung Cancer Vaccine
Gemin X Commences Clinical Trials of GX15-070
Antisoma and Biomira Announce Clinical Trial Results of Lung Cancer Drugs
OSI Pharmaceuticals Commences Phase III Clinical Trials of Tarceva®
Northwest Gets FDA Clearance to Conduct Clinical Trials for Lung Cancer Vaccine
University of Kentucky Conducts Clinical Trials on Lung Cancer Vaccine
Poniard Enrolls in Phase II Small Cell Lung Cancer Clinical Trials of Picoplatin
Sunesis Pharmaceuticals Starts Phase II Clinical Trials of SNS-595
Ligand Pharmaceuticals Tables Clinical Results of Targretin®
Bayer and Onyx Start Phase III Trial of Nexavar®
Abraxis Announces Clinical Results of ABRAXANE®
Introgen Conducts Phase II Clinical Trials of INGN 225
YM BioSciences Commences Clinical Trial of Nimotuzumab
8. RECENT INDUSTRY ACTIVITY
Merck Agrees to Merge with Shering-Plough
Abbott Molecular Signs Agreement with Genentech, OSI and Roche
IMUC Acquires Monoclonal Antibody Technology from MDC
Quest PharmaTech Enters into Collaboration with BC Cancer Agency
Daiichi Sankyo Acquires U3 Pharma
MacroGenics Takes Over Raven Biotechnologies
Roche Acquires Piramed
Bristol-Myers Squibb Acquires Kosan Biosciences
Point Therapeutics and DARA Biosciences Ink Merger Agreement
Celgene Acquires Pharmion
Pfizer to Takeover Serenex
ATS Acquires Majority Stake in GANYMED Pharmaceuticals
NCCN, AstraZeneca and Abraxis Enter into Collaboration
Eli Lilly Agrees to Take Over ImClone Systems
CytRx Takes Over Innovive Pharmaceuticals
Abbott Extends Discovery Partnership with Caprion
Bristol-Myers and ImClone to Expand the Clinical Development Program for ERBITUX
Biomoda and New Mexico Tech Enter into a Collaborative Agreement
Binex Inks Sponsored Research Agreement with MaxCyte
Simcere Pharmaceutical Acquires Master Luck
Dako Enters into Collaboration with OSI, Roche, and Genentech
Biomira and Merck Sign Revised Supply and Collaboration Agreements
ImClone Systems Terminates Development Agreement with UCB
Astellas Pharma’s US Subsidiary Acquires Agensys
Antisoma Enters into an Agreement with Novartis
Pharmacyclics Files NDA for Xcytrin® Injection
9. FOCUS ON SELECT GLOBAL PLAYERS
AstraZeneca PLC (UK)
Bristol-Myers Squibb Co. (US)
Eli Lilly & Co. (US)
F. Hoffmann-La Roche Ltd (Switzerland)
Genentech, Inc. (US)
GlaxoSmithKline Plc (UK)
Novartis Pharmaceuticals Corporation (US)
OSI Pharmaceuticals, Inc. (US)
Sanofi-Aventis (France)
Companies with Pipeline Drugs
AbGenomics International Inc. (US)
ImClone Systems, Inc. (US)
Pfizer, Inc. (US)
Merck Serono International S.A. (Switzerland)
Merck & Co. Ltd. (US)
Telik, Inc. (US)
Woomera Therapeutics, Inc. (US)
10. GLOBAL MARKET PERSPECTIVE
III. MARKET
1. THE UNITED STATES
A. MARKET ANALYSIS
NSCLC Drug Market to Rise Sharply
Lung Cancer Prevalence
A Major Cause of Death among US Women
Statistics
Market Scenario
FDA Places New Restrictions on Iressa
Innovative Technology Enables Early Diagnosis of Lung Cancer
Avastin to Emerge as the Preferred NSCLC Drug in the US
Product Approvals/Clinical Trials/Introductions/ Launches
Strategic Corporate Developments
Key Players
B. MARKET ANALYTICS
2. EUROPE
A. MARKET ANALYSIS
Lung Cancer Therapeutics Market to Witness Robust Growth
Product Approvals
Clinical Trials
B. MARKET ANALYTICS
2A.FRANCE
A. MARKET ANALYSIS
Overview of Lung Cancer Market
Key Player
B. MARKET ANALYTICS
2B.GERMANY
A. MARKET ANALYSIS
Lung Cancer Scenario
Chemotherapy Gains Preference
Strategic Corporate Developments
B. MARKET ANALYTICS
2C.ITALY
A. MARKET ANALYSIS
Incidence in Women on Rise
Treatment
B. MARKET ANALYTICS
2D.THE UNITED KINGDOM
A. MARKET ANALYSIS
British Women at Higher Risk
Fast Facts
Proposed Cancer Care Improvements Mulled by British Government
NICE Recommends Use of Erlotinib in NSCLC Treatment
Strategic Corporate Developments
Key Players
B. MARKET ANALYTICS
2E.REST OF EUROPE
A. MARKET ANALYSIS
Outlook
Strategic Corporate Developments
Key Player
B. MARKET ANALYTICS
3. REST OF WORLD
A. MARKET ANALYSIS
Australia
Fast Facts
Brazil
China
Overview of NSCLC Drug Market
India
Japan
Product Launches
Strategic Corporate Development
B. MARKET ANALYTICS
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 191 (including Divisions/Subsidiaries - 200)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Rest of Europe
Asia-Pacific (Excluding Japan)
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Chemotherapy Drugs
Targeted Drugs
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Lung Cancer Therapeutics – Driven by Next Generation Drugs
New Therapies Drive NSCLC Market
Market Value of Taxanes to Decrease by 2015
Lung Cancer – The Killer Disease
Lung Cancer – A Quick Glance at Global Statistics
Asia Heading for Possible Lung Cancer Epidemic
Table 1. Global Incidence of Lung Cancer (2008): Percentage Share Breakdown by Region (includes corresponding Graph/Chart)
2. LUNG CANCER – AN INSIGHT
Lungs – Critical for Oxygen Supply
Lung Cancer – An Introduction
Common Symptoms of Lung Cancer
Types of Lung Cancer
Non-Small Cell Lung Cancer
NSCLC – At a Glance
Small Cell Lung Cancer
Risk Factors for Lung Cancer
Female Smokers at Higher Risk of Developing Lung Cancer
Lung Cancer Diagnostics
Lung Cancer Staging
Staging for Non-Small Cell Lung Cancer
Staging for Small Cell Lung Cancer
3. LUNG CANCER TREATMENT MODALITIES
Surgery
Radiation Therapy
Chemotherapy
Combination Therapy
Photodynamic Therapy
Vaccines
Common Treatment Modalities for SCLC and NSCLC Lung Cancers
Pain Management
4. INTRODUCTION TO LUNG CANCER THERAPEUTICS
Chemotherapy
Drug Administration
Overview of Chemotherapy Regimens and Drugs
Side Effects of Chemotherapy
Targeted Therapy
Chemotherapy Drugs for SCLC Treatment
Chemotherapy Drugs for NSCLC Treatment
Major Chemotherapy Drugs
Select Chemotherapy Drugs Used in the Treatment of Lung Cancer by Brand and Generic Name
Overview of Select Chemotherapeutic Drugs
Alimta
Carboplatin and Cisplatin
Docetaxel
Paclitaxel
Xyotax
Gemcitabine
Gefitinib
Irinotecan
Vinorelbine (Navelbine®)
5. PRODUCT DEVELOPMENT IN NSCLC THERAPEUTICS
R&D Focus in NSCLC Treatment
Drug Development Process – Growth Opportunities & Challenges
Product Pipeline for NSCLC Treatment
Product Pipeline for NSCLC Treatment
Select (Ongoing/Completed) Clinical Trials for NSCLC Treatment
Companies Focus on Molecular Targeted Therapies
Molecular Targeted Therapies – Overview of Select Product Candidates
Aflibercept (VEGF-Trap) – Sanofi Aventis/ Regeneron
BIBW 2992 – Boehringer Ingelheim
Erbitux (cetuximab) - ImClone/Merck Serono/Bristol- Myers Squibb
Nexavar (sorafenib) - Bayer Schering
Recentin (cediranib) – AstraZeneca
Sutent (sunitinib) – Pfizer
Zactima (vandetanib) – AstraZeneca
Zolinza (vorinostat) – Merck & Co
Pipeline for Cytotoxic Therapy – Overview of Select Products
Abraxane (albumin-bound paclitaxel) - Abraxis
Glutoxim (NOV-002) - Novelos
Javlor (vinflunine) – Pierre Fabre
Lipoplatin (liposomal cisplatin) – Regulon
Xyotax (paclitaxel polyglumex) - Cell Therapeutics/ Novartis
6. PRODUCT APPROVALS/INNOVATIONS/ LAUNCHES
Intas Biopharmaceuticals to Introduce Gefitinib in India
Celgene Receives FDA Fast Track Product Designation for Amrubicin
EMEA Approves ALIMTA for First-Line Therapy of Advanced NSCLC
Celgene’s Cancer Drug Receives Orphan Drug Status from European Commission
Alimta Receives FDA Approval
Roche Receives Approval from European Authorities for Avastin
OSI Pharmaceuticals Introduces Tarceva in Japan
Shanghai Medipharm Introduces TNT Antibody for Treating Lung Cancer
Natco Pharma Unveils an Injectible Drug for Lung Cancer, Pemnat
Roche Scientific Introduces Tarceva in the Indian Market
GlaxoSmithKline’s HYCAMTIN® Receives Marketing Approval from EC
Genzyme Launches New Genetic Mutation Test to Aid Lung Cancer Treatment
UT Southwestern Medical Center Researchers Discover New Anti-Cancer Drug
Agennix's Talactoferrin Alfa Program Obtains Fast Track Designation from FDA
Novelos Therapeutics’ NOV-002 Receives Fast Track Designation from FDA
7.RESEARCH & CLINICAL TRIALS
Novartis Commences Phase III Clinical Trial of ASA404
Results of BR.21 Trials
Genentech Announces Results of Phase III BETA Lung Trial
Results of SATURN Clinical Trial
Results of Zactima’s Clinical Trials
Results of Erbitux’s Phase III Trials
Results of Roche’s AVAiL Clinical Trial
GlaxoSmithKline Conducts Phase III Clinical Trial of Lung Cancer Vaccine
FASgen Announces Research Results of FAS093
The Cuban Regulatory Agency Registers a New Therapeutic Lung Cancer Vaccine
Gemin X Commences Clinical Trials of GX15-070
Antisoma and Biomira Announce Clinical Trial Results of Lung Cancer Drugs
OSI Pharmaceuticals Commences Phase III Clinical Trials of Tarceva®
Northwest Gets FDA Clearance to Conduct Clinical Trials for Lung Cancer Vaccine
University of Kentucky Conducts Clinical Trials on Lung Cancer Vaccine
Poniard Enrolls in Phase II Small Cell Lung Cancer Clinical Trials of Picoplatin
Sunesis Pharmaceuticals Starts Phase II Clinical Trials of SNS-595
Ligand Pharmaceuticals Tables Clinical Results of Targretin®
Bayer and Onyx Start Phase III Trial of Nexavar®
Abraxis Announces Clinical Results of ABRAXANE®
Introgen Conducts Phase II Clinical Trials of INGN 225
YM BioSciences Commences Clinical Trial of Nimotuzumab
8. RECENT INDUSTRY ACTIVITY
Merck Agrees to Merge with Shering-Plough
Abbott Molecular Signs Agreement with Genentech, OSI and Roche
IMUC Acquires Monoclonal Antibody Technology from MDC
Quest PharmaTech Enters into Collaboration with BC Cancer Agency
Daiichi Sankyo Acquires U3 Pharma
MacroGenics Takes Over Raven Biotechnologies
Roche Acquires Piramed
Bristol-Myers Squibb Acquires Kosan Biosciences
Point Therapeutics and DARA Biosciences Ink Merger Agreement
Celgene Acquires Pharmion
Pfizer to Takeover Serenex
ATS Acquires Majority Stake in GANYMED Pharmaceuticals
NCCN, AstraZeneca and Abraxis Enter into Collaboration
Eli Lilly Agrees to Take Over ImClone Systems
CytRx Takes Over Innovive Pharmaceuticals
Abbott Extends Discovery Partnership with Caprion
Bristol-Myers and ImClone to Expand the Clinical Development Program for ERBITUX
Biomoda and New Mexico Tech Enter into a Collaborative Agreement
Binex Inks Sponsored Research Agreement with MaxCyte
Simcere Pharmaceutical Acquires Master Luck
Dako Enters into Collaboration with OSI, Roche, and Genentech
Biomira and Merck Sign Revised Supply and Collaboration Agreements
ImClone Systems Terminates Development Agreement with UCB
Astellas Pharma’s US Subsidiary Acquires Agensys
Antisoma Enters into an Agreement with Novartis
Pharmacyclics Files NDA for Xcytrin® Injection
9. FOCUS ON SELECT GLOBAL PLAYERS
AstraZeneca PLC (UK)
Bristol-Myers Squibb Co. (US)
Eli Lilly & Co. (US)
F. Hoffmann-La Roche Ltd (Switzerland)
Genentech, Inc. (US)
GlaxoSmithKline Plc (UK)
Novartis Pharmaceuticals Corporation (US)
OSI Pharmaceuticals, Inc. (US)
Sanofi-Aventis (France)
Companies with Pipeline Drugs
AbGenomics International Inc. (US)
ImClone Systems, Inc. (US)
Pfizer, Inc. (US)
Merck Serono International S.A. (Switzerland)
Merck & Co. Ltd. (US)
Telik, Inc. (US)
Woomera Therapeutics, Inc. (US)
10. GLOBAL MARKET PERSPECTIVE
Table 2. World Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market by Geographic Region – US, Europe and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)
Table 3. World 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics by Geographic Region – Percentage Breakdown of Annual Revenues for US, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
III. MARKET
1. THE UNITED STATES
A. MARKET ANALYSIS
NSCLC Drug Market to Rise Sharply
Lung Cancer Prevalence
A Major Cause of Death among US Women
Statistics
Market Scenario
FDA Places New Restrictions on Iressa
Innovative Technology Enables Early Diagnosis of Lung Cancer
Avastin to Emerge as the Preferred NSCLC Drug in the US
Product Approvals/Clinical Trials/Introductions/ Launches
Strategic Corporate Developments
Key Players
B. MARKET ANALYTICS
Table 4. US Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics by Segment – Chemotherapy Drugs and Targeted Drugs Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)
Table 5. US 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics by Segment – Percentage Breakdown of Annual Revenues for Chemotherapy Drugs and Targeted Drugs Markets for Years 2006, 2009 & 2015
2. EUROPE
A. MARKET ANALYSIS
Lung Cancer Therapeutics Market to Witness Robust Growth
Product Approvals
Clinical Trials
B. MARKET ANALYTICS
Table 6. European Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics by Geographic Region – France, Germany, Italy, UK and Rest of Europe Independently Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)
Table 7. European 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics Market by Geographic Region – Percentage Breakdown of Annual Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
2A.FRANCE
A. MARKET ANALYSIS
Overview of Lung Cancer Market
Key Player
B. MARKET ANALYTICS
Table 8. French Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)
2B.GERMANY
A. MARKET ANALYSIS
Lung Cancer Scenario
Chemotherapy Gains Preference
Strategic Corporate Developments
B. MARKET ANALYTICS
Table 9. German Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)
2C.ITALY
A. MARKET ANALYSIS
Incidence in Women on Rise
Treatment
B. MARKET ANALYTICS
Table 10. Italian Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)
2D.THE UNITED KINGDOM
A. MARKET ANALYSIS
British Women at Higher Risk
Fast Facts
Proposed Cancer Care Improvements Mulled by British Government
NICE Recommends Use of Erlotinib in NSCLC Treatment
Strategic Corporate Developments
Key Players
B. MARKET ANALYTICS
Table 11. UK Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)
2E.REST OF EUROPE
A. MARKET ANALYSIS
Outlook
Strategic Corporate Developments
Key Player
B. MARKET ANALYTICS
Table 12. Rest of Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)
3. REST OF WORLD
A. MARKET ANALYSIS
Australia
Fast Facts
Brazil
China
Overview of NSCLC Drug Market
India
Japan
Product Launches
Strategic Corporate Development
B. MARKET ANALYTICS
Table 13. Rest of World Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 191 (including Divisions/Subsidiaries - 200)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Rest of Europe
Asia-Pacific (Excluding Japan)
